Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Liabilities and Shareholders Equity (2020 - 2026)

Unicycive Therapeutics filings provide 4 years of Liabilities and Shareholders Equity readings, the most recent being $31.7 million for Q4 2024.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 123.16% to $31.7 million in Q4 2024 year-over-year; TTM through Dec 2024 was $167.3 million, a 99.87% increase, with the full-year FY2024 number at $31.7 million, up 123.16% from a year prior.
  • Liabilities and Shareholders Equity hit $31.7 million in Q4 2024 for Unicycive Therapeutics, down from $38.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $52.4 million in Q1 2024 to a low of $2.8 million in Q4 2022.
  • Median Liabilities and Shareholders Equity over the past 4 years was $19.4 million (2023), compared with a mean of $24.0 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 84.97% in 2022 and later soared 403.58% in 2023.
  • Unicycive Therapeutics' Liabilities and Shareholders Equity stood at $18.7 million in 2021, then plummeted by 84.97% to $2.8 million in 2022, then soared by 403.58% to $14.2 million in 2023, then skyrocketed by 123.16% to $31.7 million in 2024.
  • The last three reported values for Liabilities and Shareholders Equity were $31.7 million (Q4 2024), $38.6 million (Q3 2024), and $44.7 million (Q2 2024) per Business Quant data.